80 related articles for article (PubMed ID: 17604542)
1. Early modification of initial HAART regimen associated with poor clinical outcome in HIV patients.
Park WB; Choe PG; Kim SH; Jo JH; Bang JH; Kim HB; Kim NJ; Oh MD; Choe KW
AIDS Res Hum Retroviruses; 2007 Jun; 23(6):794-800. PubMed ID: 17604542
[TBL] [Abstract][Full Text] [Related]
2. Effect of hepatitis C coinfection on discontinuation and modification of initial HAART in primary HIV care.
Hooshyar D; Napravnik S; Miller WC; Eron JJ
AIDS; 2006 Feb; 20(4):575-83. PubMed ID: 16470122
[TBL] [Abstract][Full Text] [Related]
3. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.
Cicconi P; Cozzi-Lepri A; Castagna A; Trecarichi EM; Antinori A; Gatti F; Cassola G; Sighinolfi L; Castelli P; d'Arminio Monforte A;
HIV Med; 2010 Feb; 11(2):104-13. PubMed ID: 19732176
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
Gutierrez F; Padilla S; Masiá M; Iribarren JA; Moreno S; Viciana P; Muñoz L; Gómez Sirvent JL; Vidal F; López-Aldeguer J; Blanco JR; Leal M; Rodríguez-Arenas MA; Perez Hoyos S;
PLoS One; 2006 Dec; 1(1):e89. PubMed ID: 17183720
[TBL] [Abstract][Full Text] [Related]
5. One-year adherence to clinic visits after highly active antiretroviral therapy: a predictor of clinical progress in HIV patients.
Park WB; Choe PG; Kim SH; Jo JH; Bang JH; Kim HB; Kim NJ; Oh M; Choe KW
J Intern Med; 2007 Mar; 261(3):268-75. PubMed ID: 17305649
[TBL] [Abstract][Full Text] [Related]
6. Costs and benefits of HAART for patients with HIV in a public hospital in Mexico.
Aracena-Genao B; Navarro JO; Lamadrid-Figueroa H; Forsythe S; Trejo-Valdivia B
AIDS; 2008 Jul; 22 Suppl 1():S141-8. PubMed ID: 18664946
[TBL] [Abstract][Full Text] [Related]
7. Incidence of modifying or discontinuing first HAART regimen and its determinants in a cohort of HIV-infected patients from Rio de Janeiro, Brazil.
Cardoso SW; Grinsztejn B; Velasque L; Veloso VG; Luz PM; Friedman RK; Morgado M; Ribeiro SR; Moreira RI; Keruly J; Moore RD
AIDS Res Hum Retroviruses; 2010 Aug; 26(8):865-74. PubMed ID: 20672997
[TBL] [Abstract][Full Text] [Related]
8. Rate of initial highly active anti-retroviral therapy regimen change and its predictors among adult HIV patients at University of Gondar Referral Hospital, Northwest Ethiopia: a retrospective follow up study.
Anlay DZ; Alemayehu ZA; Dachew BA
AIDS Res Ther; 2016; 13():10. PubMed ID: 26889204
[TBL] [Abstract][Full Text] [Related]
9. Effects of pill burden on discontinuation of the initial HAART regimen in minority female patients prescribed 1 pill/day versus any other pill burden.
Hill S; Kavookjian J; Qian J; Chung A; Vandewaa J
AIDS Care; 2014; 26(5):595-601. PubMed ID: 24111921
[TBL] [Abstract][Full Text] [Related]
10. Duration of highly active antiretroviral therapy regimens.
Chen RY; Westfall AO; Mugavero MJ; Cloud GA; Raper JL; Chatham AG; Acosta EP; Taylor KH; Carter J; Saag MS
Clin Infect Dis; 2003 Sep; 37(5):714-22. PubMed ID: 12942406
[TBL] [Abstract][Full Text] [Related]
11. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
[TBL] [Abstract][Full Text] [Related]
12. The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART.
Castor D; Vlahov D; Hoover DR; Berkman A; Wu YF; Zeller B; Brechtl J; Hammer SM
J Med Virol; 2009 Aug; 81(8):1323-35. PubMed ID: 19551816
[TBL] [Abstract][Full Text] [Related]
13. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
Taha TE; Kumwenda J; Cole SR; Hoover DR; Kafulafula G; Fowler MG; Thigpen MC; Li Q; Kumwenda NI; Mofenson L
J Infect Dis; 2009 Nov; 200(10):1490-7. PubMed ID: 19832114
[TBL] [Abstract][Full Text] [Related]
14. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.
Rodríguez-Arenas MA; Jarrín I; del Amo J; Iribarren JA; Moreno S; Viciana P; Peña A; Sirvent JL; Vidal F; Lacruz J; Gutierrez F; Oteo JA; Asencio R; Castilla J; Hoyos SP;
AIDS Res Hum Retroviruses; 2006 Aug; 22(8):715-23. PubMed ID: 16910826
[TBL] [Abstract][Full Text] [Related]
15. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
[TBL] [Abstract][Full Text] [Related]
16. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
17. High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection.
Sabundayo BP; McArthur JH; Langan SJ; Gallant JE; Margolick JB
Pharmacotherapy; 2006 May; 26(5):674-81. PubMed ID: 16637796
[TBL] [Abstract][Full Text] [Related]
18. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.
Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
HIV Med; 2007 Mar; 8(2):80-5. PubMed ID: 17352763
[TBL] [Abstract][Full Text] [Related]
19. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
20. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
